NCT00634309已完成3 期
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Depressed Left Ventricular Systolic Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 597
- 主要终点
- Cardiovascular mortality or hospitalisation due to congestive heart failure
研究概览
简要总结
A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged 18 or above
- •Congestive Heart Failure with symptoms for more than 4 weeks before starting study
- •Provision of informed consent
排除标准
- •Current low blood pressure with symptoms
- •Liver disease considered significant by the study doctor
- •Pregnant or lactating females
研究组 & 干预措施
1
Active Comparator
干预措施: Candesartan (Drug)
2
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Cardiovascular mortality or hospitalisation due to congestive heart failure
时间窗: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months
次要结局
- Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI(2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months)
研究者
相似试验
已完成
3 期
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)Congestive Heart FailureNCT00634712AstraZeneca734
已完成
3 期
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)Congestive Heart FailureNCT00634400AstraZeneca6,268
已完成
不适用
Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in FranceCohort StudyHeart FailureNCT00679640AstraZeneca450
招募中
不适用
Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart FailureLevosimendanHeart FailureEfficacySafetyNCT05913271Yi Han352
已完成
3 期
Diabetic Retinopathy Candesartan TrialsType 1 DiabetesNCT00252733AstraZeneca5,238